Shenzhen Kangtai Biological Products will produce AstraZeneca's potential COVID-19 vaccine in mainland China, marking the UK drugmaker's first supply deal with a Chinese company for AZD1222, as reported in London South East.
According to AstraZeneca, Shenzhen Kangtai will ensure it has annual production capacity of at least 100 million doses of AZD1222, which is being co-developed with Oxford University, by the end of this year.
It must have capacity to produce at least 200 million doses by the end of next year as part of the exclusive framework agreement, its statement on the Chinese social media site WeChat added.
AstraZeneca indicated that the two firms will also explore the possibility of cooperation on the vaccine candidate in other markets.
To read more NewsPoints articles, click here.